Concall notes for Q3FY24
- 1 oncology product to be launched in April
- Import substitute
- Some addition in non-oncology by Dec 2024 – will add revenue addition
- 1 CEP of peptide product filled in Europe
- Very optimistic about API business
- Biologics has been a pain point in last 4-5 qtrs
- +ve ebitda this quarter
- Positively focusing here
- Aflibercept – phase 3 studies to start in April
- 1 yr study
- Rs 4 cr receivable provision
- Rs 146 cr capex of which Rs 117 cr invested in Albumin capacity
- Total investment made in Albumin – Rs 300 cr +
- More 40 cr required
- Phase 2 study to complete by FY25 end
- Polymer revenue in 2-3 yrs –
- This yr 15 cr
- 2-3 yrs 100 cr
- Biologics –
- 1st phase to complete by April ( Value = 6 cr) phase 2 also 6 cr
- Dip in oncology revenue because of remediation reasons
- Transdermal & ODF – Rs 200 cr investment
- Breakevens in fy26
- Biologics : EBITDA + ve next qtr
- Targeting to reduce debt significantly in 2-3 yrs
- They said current capex in Biologics and Transdermal is underutilised
- Not possible to share utilisation numbers as there are several units, doing different products
- For revenue potential of capex – they said its too early to comment. They’ll share numbers when products are near launch
- Albumin will take at least 1.5 yrs from now. Its about to enter phase 2
- The products are in short supply with high demand
Would be better able to analyse the company if get the utilisation numbers and potential of last capex. – the one it did in last 4 years.
Looking forward to your contribution.
| Subscribe To Our Free Newsletter |
